Kim, S. T., Jang, K., Lee, S. J., Jang, H., Lee, J., Park, S. H., . . . Park, J. O. (2015). Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer.
Citação norma ChicagoKim, Seung Tae, et al. "Tumour Shrinkage At 6 weeks Predicts Favorable Clinical Outcomes in a Phase III Study of Gemcitabine and Oxaliplatin With or Without Erlotinib for Advanced Biliary Tract Cancer." BMC Cancer 2015.
Citação norma MLAKim, Seung Tae, et al. "Tumour Shrinkage At 6 weeks Predicts Favorable Clinical Outcomes in a Phase III Study of Gemcitabine and Oxaliplatin With or Without Erlotinib for Advanced Biliary Tract Cancer." BMC Cancer 2015.